Loading company…
Pharvaris is a clinical-stage biotechnology company developing orally taken drugs for hereditary angioedema (HAE).
Founded in 2015 and based in Zug, Switzerland, Pharvaris GmbH develops orally taken small-molecule bradykinin B2-receptor antagonists for hereditary angioedema (HAE). The company raised a total of USD 162.3 million across Series A, B and C rounds in 2016, 2019 and 2020, and raised USD 165.41 million in an IPO in February 2021, selling 8.27 million shares at USD 20 per share on NASDAQ. Berndt Modig is Director and CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in